Answers are grounded in this paper and cite their sources.
The use of a specifically adapted workflow enabled identification of pathogenic autosomal CNVs in 10.9% of patients with epilepsy plus, which rose to 12.7% when we also considered possibly pathogenic CNVs. Our data indicate that epilepsy with comorbid features should be considered an indication for patients to be selected for a diagnostic algorithm including CNV detection. Collaborative large-scale CNV reanalysis leads to novel declaration of pathogenicity in unexplained cases and can promote discovery of promising candidate epilepsy genes.
No takes yet. Share an insight, caveat, or question.
Coppola et al. (2019) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: